Endocrine Abstracts

Pituitary adenomas (PA) comprise a commonly underestimated pathology in terms of incidence and associated morbi-mortality. Although somatostatin analogs and dopamine antagonists constitute the main medical treatments for PAs, an appreciable subset of patients are resistant or poorly responsive to these drugs and hence is crucial the search for new therapies. Biguanides such as metformin (MF; commonly used to treat type-2 diabetes), phenformin (PF) and buformin (BF) have been s...

Objectives: The transition from the paediatric age to the adult is a particularly vulnerable period in patients with metabolic congenital diseases (mcd). In andalusia two adults’ units exist (seville and malaga) for the follow-up of these patients. Our aim in this study was to evaluate the current series of attended patients.Material and methods: We evaluated all patients transferred to the adult units since 2008. The clinical records were analyzed ...

Pituitary adenomas are usually benign. However, a significant number of pituitary adenomas show an aggressive behaviour, with local invasion, increased risk of recurrence after surgery and lack of therapeutic response. In this study, we aimed to determine whether invasive and non-invasive pituitary adenomas display differences in clinical features and molecular parameters. In this retrospective descriptive study, 46 pituitary adenomas were analysed. Invasiveness was defined as...

Objectives: The primary objective was to determine if the use of Contour Next One (CNO) with Contour Diabetes app (APP) was associated with improved self-management using the Summary of Diabetes Self-Care Activities questionnaire (SDSCA). A secondary objective was to establish if CNO and APP together had impact on adherence to self-monitoring blood glucose (BG), indicated by frequency of BG readings and hypoglycemic events. Other secondary objectives were to observe a possible...

Introduction: Neuroendocrine tumors (NETs) are rare and their clinical behavior and prognosis correlates with mitotic rate and Ki-67 index. Most patients with advanced NET have liver metastases unresectable and somatostatin analogues are the initial therapy of choice but when disease progresses despite treatment and there are positive somatostatin receptors, peptide receptor radioligand therapy (PRRT), using lutetium-177, is a therapeutic option.Clinical...

Introduction: Non-functioningpituitary adenomas (NFPAs) are of benign nature but a sizeable number of NFPAs show aggressive features. Surgery is not always effective in treating NFPAs and thus other therapeutic options are needed. Previous studies have reported that NFPAs express somastostatin receptors (SSTRs) and dopamine receptors (DRDs).Aim: To systematically analyze the expression of SSTRs and DRDs in a large cohort of clinically well-characterized ...

Methods: Restrospective descriptive study of patients who underwent ETPS for pituitary adenoma removal performed by the same surgical team in Virgen del Rocio Hospital of Seville from January 2014 to January 2019.Results: 174 patients had a pituitary adenoma (44 GH, 36 ACTH, 94 Non functioning). 54.02% were female. In acromegaly, 39 (88.63%) patients were operated by ETPS as initial approach. 20 (51.28%) patients had cavernous sinus invation. At outcome ...

Introduction: Acromegaly increases morbidity and mortality and should be treated even in the asymptomatic phase. It is almost always caused by a GH-producing pituitary adenoma and although transsphenoidal surgery is the treatment of choice in most cases, in others, primary medical therapy is indicated.Clinical case: A 36-year-old female with a family history of thyroid functional pathology and diagnosed with micronodular goiter was evaluated in February ...

Aim: To assess whether E-cadherin expression levels in somatotropinomas were associated with the response to somatostatin analogues (SSAs) therapy in patients with acromegaly.Methods: In this retrospective study, 56 acromegaly patients that underwent transsphenoidal surgery were evaluated. All patients were treated preoperatively with SSAs (octreotide or lanreotide) for at least 6 months. Responsiveness to SSAs was evaluated by percent IGF-1 reduction af...

Pituitary adenomas (PA), as well as pheochromocytomas and paragangliomas, are neuroendocrine tumors that arise from cells derived from the pituitary, adrenal and extra-adrenal nervous system, respectively. Recent studies have identified a growing series of susceptibility genes for these pathologies. Some genes may be associated with the development of both types of pathologies, as it is the case for succinate dehydrogenase complex genes, while, PAs have not been reported to da...